Kenya - English - Pharmacy and Poisons Board

krishna chemists ltd 3rd floor metrix hardware, lusaka road, - azilsartan 80mg - tablet - 80mg - azilsartan medoxomil

Kenya - English - Pharmacy and Poisons Board

krishna chemists ltd 3rd floor metrix hardware, lusaka road, - azilsartan 80mg + hctz 12.5mg - tablet - 80 mg + 12.5mg - azilsartan medoxomil

United States - English - NLM (National Library of Medicine)

remedyrepack inc. - lamotrigine (unii: u3h27498ks) (lamotrigine - unii:u3h27498ks) - lamotrigine extended-release tablets are indicated as adjunctive therapy for primary generalized tonic-clonic (pgtc) seizures and partial-onset seizures with or without secondary generalization in patients aged 13 years and older. lamotrigine extended-release tablets are indicated for conversion to monotherapy in patients aged 13 years and older with partial-onset seizures who are receiving treatment with a single antiepileptic drug (aed). safety and effectiveness of lamotrigine extended-release tablets have not been established (1) as initial monotherapy or (2) for simultaneous conversion to monotherapy from 2 or more concomitant aeds. safety and effectiveness of lamotrigine extended-release tablets for use in patients younger than 13 years have not been established. lamotrigine extended-release is contraindicated in patients who have demonstrated hypersensitivity (e.g., rash, angioedema, acute urticaria, extensive pruritus, mucosal ulceration) to the drug or its ingredients [see boxed warning, warnings and

United States - English - NLM (National Library of Medicine)

remedyrepack inc. - lamotrigine (unii: u3h27498ks) (lamotrigine - unii:u3h27498ks) - lamotrigine extended-release tablets are indicated as adjunctive therapy for primary generalized tonic-clonic (pgtc) seizures and partial-onset seizures with or without secondary generalization in patients aged 13 years and older. lamotrigine extended-release tablets are indicated for conversion to monotherapy in patients aged 13 years and older with partial-onset seizures who are receiving treatment with a single antiepileptic drug (aed). safety and effectiveness of lamotrigine extended-release tablets have not been established (1) as initial monotherapy or (2) for simultaneous conversion to monotherapy from 2 or more concomitant aeds. safety and effectiveness of lamotrigine extended-release tablets for use in patients younger than 13 years have not been established. lamotrigine extended-release tablets are contraindicated in patients who have demonstrated hypersensitivity (e.g., rash, angioedema, acute urticaria, extensive pruritus, mucosal ulceration) to the drug or its ingredients [see boxed warning, warn

Malta - English - Medicines Authority

novartis ireland limited vista building, elm park, merrion road, ballsbridge, dublin 4,, ireland - carbamazepine - tablet - carbamazepine 200 mg - antiepileptics

Singapore - English - HSA (Health Sciences Authority)

takeda pharmaceuticals (asia pacific) pte. ltd. - azilsartan medoxomil potassium 42.68mg eqv azilsartan medoxomil - tablet - 40mg

Singapore - English - HSA (Health Sciences Authority)

takeda pharmaceuticals (asia pacific) pte. ltd. - azilsartan medoxomil potassium 42.68mg eqv azilsartan medoxomil - tablet - 40mg

United States - English - NLM (National Library of Medicine)

takeda pharmaceuticals america, inc. - azilsartan kamedoxomil (unii: wec6i2k1fc) (azilsartan - unii:f9nux55p23) - azilsartan medoxomil 40 mg

European Union - English - EMA (European Medicines Agency)

teva b.v. - rasagiline - parkinson disease - anti-parkinson drugs - azilect is indicated for the treatment of idiopathic parkinson's disease (pd) as monotherapy (without levodopa) or as adjunct therapy (with levodopa) in patients with end-of-dose fluctuations.

United States - English - NLM (National Library of Medicine)

takeda pharmaceuticals america, inc. - azilsartan kamedoxomil (unii: wec6i2k1fc) (azilsartan - unii:f9nux55p23) - azilsartan medoxomil 40 mg